VisCardia Inc. is a Heart Failure (HF) management company focused on commercialization of a novel implantable medical device therapy and addressing the significant gap in cardiovascular clinical indications. The company’s initial focus is on the underserved group of moderate to severe systolic HF (NYHA II-III) patients refractory to guideline directed medical therapy with reduced Ejection Fraction (LVEF < 35%), and preserved ventricular synchrony (narrow QRS).
While other heart failure technologies attempt to encourage the weakened heart to work harder, the VisONE therapy makes it easier for the weak heart to work better.
ACC.20/WCC Learning Pathways? (select all that apply) Acute and Stable Ischemic Heart Disease, Heart Failure and Cardiomyopathies, Interventional Cardiology